FDA Approves Xocova as First Oral COVID-19 Post-Exposure Prevention Drug, Based on Phase 3 Trial Showing 67% Risk Reduction
The FDA has approved Shionogi's ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19, the first oral antiviral cleared for that indication in the US.
4 min read5 sources